From GlobeNewswire: 2025-06-12 09:40:00

The Non-alcoholic Steatohepatitis Biomarkers Market was valued at USD 1.14 billion in 2023, projected to reach USD 9.1 billion by 2032, with a CAGR of 25.9%. Rising NASH prevalence and adoption of non-invasive diagnostics are driving market growth, supported by AI-based solutions and biomarker assay innovations.

Industry leaders focus on AI-based biomarker assays, proteomic innovation, and partnerships to improve NASH detection. Pharmaceutical firms and CROs lead using biomarkers to enhance clinical trials. Regulatory approvals and increasing investments in biomarkers will drive market growth significantly.

North America dominated the NASH Biomarkers Market in 2023 with 40% share, driven by a strong healthcare infrastructure and high NASH prevalence. Asia Pacific is expected to show the highest growth due to increasing NAFLD burden and adoption of biomarker-based diagnostics, supported by government initiatives and regulatory backing.

Siemens Healthineers released a next-gen NASH biomarker assay integrating serum markers via AI algorithms. AstraZeneca and Novo Nordisk collaborated on a biomarker platform for personalized NASH treatments. Global NASH prevalence was 5-6% in 2023, with North America and Europe most affected. Biomarker assay numbers for NASH are projected to quadruple by 2032, reflecting increasing non-invasive diagnostic adoption.



Read more at GlobeNewswire: Non-alcoholic Steatohepatitis Biomarkers Market to Hit USD